Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,622 shares of the biopharmaceutical company’s stock after acquiring an additional 472 shares during the period. Fisher Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $4,938,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Capital World Investors lifted its stake in shares of Regeneron Pharmaceuticals by 0.5% during the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after buying an additional 23,146 shares during the period. Putnam Investments LLC lifted its stake in shares of Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after buying an additional 24,329 shares during the period. Northern Trust Corp lifted its stake in shares of Regeneron Pharmaceuticals by 3.3% during the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock worth $878,271,000 after buying an additional 34,326 shares during the period. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $932,571,000. Finally, Morgan Stanley lifted its stake in shares of Regeneron Pharmaceuticals by 2.7% during the third quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock worth $799,061,000 after buying an additional 25,792 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $1,044.39 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $1,052.34. The firm’s 50 day moving average price is $964.87 and its 200 day moving average price is $941.08. The company has a market cap of $115.08 billion, a P/E ratio of 30.85, a PEG ratio of 2.15 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

REGN has been the subject of several research reports. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price objective for the company. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. Finally, TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $998.09.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 787 shares of the stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total value of $798,820.74. Following the sale, the chief executive officer now directly owns 64,198 shares of the company’s stock, valued at approximately $65,162,253.96. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Michael S. Brown sold 1,535 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total value of $1,596,400.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,437,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Leonard S. Schleifer sold 787 shares of the stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total transaction of $798,820.74. Following the completion of the transaction, the chief executive officer now directly owns 64,198 shares in the company, valued at $65,162,253.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 61,215 shares of company stock valued at $60,414,782. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.